Anhui Provincial Hospital
Anhui Provincial Hospital
Hefei, Anhui, China28 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 1 / Phase 2 | 2026-10-09 | NCT06139575 | |
| Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Recruiting | Phase 3 | 2026-09-17 | NCT07687459 | |
| A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-09-17 | NCT06361888 | |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-09-03 | NCT04588922 | |
| Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Phase 2 | 2026-09-01 | NCT07796516 | |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bile duct disorder, bile duct neoplasm, biliary tract disorder, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cholangiocarcinoma, digestive system disorder, digestive system neoplasm, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, liver disorder, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05150691 | |
| A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-07-29 | NCT07327229 | |
| A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-16 | NCT07547553 | |
| Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial | brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, nervous system disorder, stroke disorder, vascular disorder | Recruiting | Not applicable | 2026-06-15 | NCT07648693 | |
| A Study in Chinese Patients With Acquired Blepharoptosis | eye disorder, eyelid disorder, ptosis | Recruiting | Phase 3 | 2026-05-15 | NCT06683651 | |
| SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors | HER2-positive Advanced Solid Tumors | Recruiting | Early phase 1 | 2026-05-05 | NCT05245058 | |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Locally Advanced Unresectable or Metastatic Solid Tumors | Recruiting | Phase 1 | 2026-05-04 | NCT05458219 | |
| Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-03-06 | NCT06196840 | |
| A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults | Upper Limb Spasticity | Recruiting | Phase 2 / Phase 3 | 2026-01-22 | NCT06783114 | |
| Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations | Cirrhosis, Familial, with Pulmonary Hypertension, Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, neoplasm | Not yet recruiting | Phase 3 | 2026-01-09 | NCT07328919 | |
| IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm | Recruiting | Phase 3 | 2025-11-25 | NCT06647862 | |
| A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 1 | 2025-09-26 | NCT05924750 | |
| Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors | Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Liver Neoplasms, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, cervix disorder, female reproductive system disorder, female reproductive system neoplasm, liver disorder, neoplasm, uterine disorder | Recruiting | Early phase 1 | 2025-09-15 | NCT07106814 | |
| A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Recruiting | Phase 2 | 2025-08-27 | NCT06241846 | |
| Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor | Cholangiocarcinoma Metastatic | Active, not recruiting | Phase 2 | 2025-08-21 | NCT06057571 | |
| Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence | Recruiting | Phase 2 | 2025-08-05 | NCT06224257 | |
| Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. | Allergic Transfusion Reaction | Recruiting | Phase 2 | 2025-08-05 | NCT04688736 | |
| Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell leukemia, plasma cell neoplasm, proteostasis deficiencies, vascular disorder, vascular hemostatic disease | Recruiting | Early phase 1 | 2025-07-25 | NCT07085559 | |
| LX102 in Patients With Neovascular Age-Related Macular Degeneration (nAMD) | eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 1 | 2025-07-01 | NCT06198413 | |
| Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, carcinoma of esophagus, digestive system disorder, digestive system neoplasm, esophageal disorder, neoplasm | Not yet recruiting | Phase 1 | 2025-06-24 | NCT07034118 |